Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer

Bahir Aldulaymi; Ib J. Christensen; György Sölétormos; Per Jess; Svend Erik Nielsen; Nils Brunner; Hans J.  Nielsen

Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer

Bahir Aldulaymi, Ib J. Christensen, György Sölétormos, Per Jess, Svend Erik Nielsen, Nils Brunner, Hans J. Nielsen

11 Citations (Scopus)

Abstract

Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer. Patients and Methods: Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received 10-12 cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later. Results: No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later. Conclusion: Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment.

Original language	English
Journal	Anticancer Research
Volume	30
Pages (from-to)	233-237
Number of pages	5
ISSN	0250-7005
Publication status	Published - Jan 2010

Keywords

Former LIFE faculty

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

Changes in soluble CEA and TIMP 1 levels during adjuvant chemotherapy forSubmitted manuscript, 77.9 KB

Cite this

@article{903a5efd62bb4617848a69c215237f57,

title = "Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer",

abstract = "Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer. Patients and Methods: Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received 10-12 cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later. Results: No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later. Conclusion: Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment.",

keywords = "Former LIFE faculty, Biomarkers, CEA, TIMP-1, rectal cancer, chemoradiation",

author = "Bahir Aldulaymi and Christensen, {Ib J.} and Gy{\"o}rgy S{\"o}l{\'e}tormos and Per Jess and Nielsen, {Svend Erik} and Nils Brunner and Nielsen, {Hans J.}",

year = "2010",

month = jan,

language = "English",

volume = "30",

pages = "233--237",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

}

TY - JOUR

T1 - Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer

AU - Aldulaymi, Bahir

AU - Christensen, Ib J.

AU - Sölétormos, György

AU - Jess, Per

AU - Nielsen, Svend Erik

AU - Brunner, Nils

AU - Nielsen, Hans J.

PY - 2010/1

Y1 - 2010/1

N2 - Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer. Patients and Methods: Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received 10-12 cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later. Results: No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later. Conclusion: Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment.

AB - Background: Tissue inhibitor of metalloproteinases-1 (TIMP-1) has been suggested to be a valuable marker in colorectal cancer (CRC), but the effects of chemotherapy on TIMP-1 levels are unknown. The present study evaluated the effect of chemotherapy on TIMP-1 levels in comparison with carcinoembryonic antigen (CEA) levels in patients with stage III colon cancer. Patients and Methods: Thirty patients who had been curatively resected for stage III colon cancer were included. The patients received 10-12 cycles of modified FOLFOX6 regimen. Blood samples were collected before and after the first and the second cycle and three months later. Results: No significant change could be detected in CEA levels while TIMP-1 raised significantly after the second cycle but returned to normal 3 months later. Conclusion: Plasma CEA levels are stable during adjuvant chemotherapy while the plasma level of TIMP-1 might be directly affected by chemotherapy represented by a transient rise about 2 weeks following the initiation of treatment.

KW - Former LIFE faculty

KW - Biomarkers

KW - CEA

KW - TIMP-1

KW - rectal cancer

KW - chemoradiation

M3 - Journal article

SN - 0250-7005

VL - 30

SP - 233

EP - 237

JO - Anticancer Research

JF - Anticancer Research

ER -

Changes in soluble CEA and TIMP-1 levels during adjuvant chemotherapy for stage III colon cancer

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this